



## MS4A1

### Research Grade Rituximab

<b>Catalog No.</b>	DHC90705A DHC90705B	<b>Quantity:</b>	100 µg 1.0 mg
<b>Alternate Names:</b>	IDEC-C2B8, CAS: 174722-31-7		
<b>Description:</b>	<p>Research Grade Rituximab chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. After binding to CD20, rituximab mediates B-cell lysis (or breakdown). The possible mechanisms of cell lysis include complement dependent cytotoxicity (CDC) and antibody dependent cell-mediated cytotoxicity (ADCC). The antibody is an IgG1 kappa immunoglobulin containing murine light and heavy-chain variable region sequences and human constant region sequences. It was originally approved by the U.S. FDA in 1997 as a single agent to treat patients with B-cell Non-Hodgkin's Lymphoma (NHL) and has now been approved for a variety of conditions.</p>		
<b>UniProt ID (target):</b>	P11836		
<b>Specificity:</b>	Human B-lymphocyte antigen CD20 (Bp35)		
<b>Source:</b>	XtenCHO cell line		
<b>Isotype:</b>	Chimeric IgG1 kappa		
<b>Concentration:</b>	1.0 mg/ml, lot specific		
<b>Formulation:</b>	0.01M PBS, pH 7.4		
<b>Purity:</b>	> 95% as determined by SDS-PAGE		
<b>Biological Activity:</b>	<p>Rituximab is highly efficient at mediating complement dependent cytotoxicity (CDC) of various B cell lines as well as fresh malignant B cell samples. CD20-binding capacity of rituximab is dose-dependent.  <math>EC_{50} = 0.588 \mu\text{g/ml}</math>, Rituximab binding CD20 by ELISA</p>		
<b>Endotoxin:</b>	< 0.01 EU/µg by LAL analysis		
<b>INN:</b>	Rituximab		
<b>Applications:</b>	Functional studies, ELISA		
<b>Storage &amp; Stability:</b>	Store at 2-8°C for up to 1 week, or undiluted in working aliquots at -20°C to -80°C for up to 1 year. <b>Avoid freeze/thaw cycles.</b>		



NOT FOR HUMAN USE. FOR RESEARCH ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.

